Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Frequently asked questions
What sector does Klotho Neurosciences, Inc. (KLTO) operate in?
Klotho Neurosciences, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Klotho Neurosciences, Inc. (KLTO) current stock price?
As of the latest data, Klotho Neurosciences, Inc. stock price is $0.52, with a previous close of $0.52. Klotho Neurosciences, Inc. gained $0.00 in the last trading session, representing a 0.77% increase.
What is Klotho Neurosciences, Inc. (KLTO) current market capitalization?
Klotho Neurosciences, Inc. market cap is approximately 56.64 million.
What is Klotho Neurosciences, Inc. (KLTO) Earnings Per Share (EPS)?
The trailing EPS is -$0.30.
Does Klotho Neurosciences, Inc. (KLTO) pay dividends?
No. Klotho Neurosciences, Inc. does not pay a dividend.
What is Klotho Neurosciences, Inc. (KLTO) beta (volatility) score?
Klotho Neurosciences, Inc. has a beta of 2.235, indicating very high volatility compared to the market.